WO2001035995A3 - Tr3-specific binding agents and methods for their use - Google Patents

Tr3-specific binding agents and methods for their use Download PDF

Info

Publication number
WO2001035995A3
WO2001035995A3 PCT/US2000/031692 US0031692W WO0135995A3 WO 2001035995 A3 WO2001035995 A3 WO 2001035995A3 US 0031692 W US0031692 W US 0031692W WO 0135995 A3 WO0135995 A3 WO 0135995A3
Authority
WO
WIPO (PCT)
Prior art keywords
specific binding
binding agents
methods
biologically active
agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2000/031692
Other languages
French (fr)
Other versions
WO2001035995A2 (en
Inventor
Thomas V Tittle
Keith W Wegmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CA002391530A priority Critical patent/CA2391530A1/en
Priority to JP2001537985A priority patent/JP2003514031A/en
Priority to MXPA02005069A priority patent/MXPA02005069A/en
Priority to AU17762/01A priority patent/AU784504B2/en
Priority to US10/204,419 priority patent/US6994976B1/en
Priority to EP00980509A priority patent/EP1231937A2/en
Application filed by Individual filed Critical Individual
Publication of WO2001035995A2 publication Critical patent/WO2001035995A2/en
Publication of WO2001035995A3 publication Critical patent/WO2001035995A3/en
Anticipated expiration legal-status Critical
Priority to US11/196,919 priority patent/US20050282223A1/en
Priority to AU2006202940A priority patent/AU2006202940A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Biologically active TR3-specific binding agents and methods for their use are disclosed. The biologically active TR3-specific binding agents are useful for inhibiting the proliferation of cells expressing TR3. These biologically active agents are particularly useful for treating T-cell mediated diseases such as graft-versus-host disease, organ rejection, tumor growth, autoimmunity, and inflammation.
PCT/US2000/031692 1999-11-19 2000-11-17 Tr3-specific binding agents and methods for their use Ceased WO2001035995A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
JP2001537985A JP2003514031A (en) 1999-11-19 2000-11-17 TR3-specific binding agents and methods for their use
MXPA02005069A MXPA02005069A (en) 1999-11-19 2000-11-17 Tr3 specific binding agents and methods for their use.
AU17762/01A AU784504B2 (en) 1999-11-19 2000-11-17 TR3-specific binding agents and methods for their use
US10/204,419 US6994976B1 (en) 1999-11-19 2000-11-17 Tr3-specific binding agents and methods for their use
EP00980509A EP1231937A2 (en) 1999-11-19 2000-11-17 Tr3-specific binding agents and methods for their use
CA002391530A CA2391530A1 (en) 1999-11-19 2000-11-17 Tr3-specific binding agents and methods for their use
US11/196,919 US20050282223A1 (en) 1999-11-19 2005-08-04 TR3-specific binding agents and methods for their use
AU2006202940A AU2006202940A1 (en) 1999-11-19 2006-07-10 TR3-specific binding agents and methods for their use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16658399P 1999-11-19 1999-11-19
US60/166,583 1999-11-19

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/196,919 Division US20050282223A1 (en) 1999-11-19 2005-08-04 TR3-specific binding agents and methods for their use

Publications (2)

Publication Number Publication Date
WO2001035995A2 WO2001035995A2 (en) 2001-05-25
WO2001035995A3 true WO2001035995A3 (en) 2001-11-22

Family

ID=22603921

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/031692 Ceased WO2001035995A2 (en) 1999-11-19 2000-11-17 Tr3-specific binding agents and methods for their use

Country Status (7)

Country Link
US (1) US20050282223A1 (en)
EP (1) EP1231937A2 (en)
JP (1) JP2003514031A (en)
AU (2) AU784504B2 (en)
CA (1) CA2391530A1 (en)
MX (1) MXPA02005069A (en)
WO (1) WO2001035995A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9017679B2 (en) 2005-08-30 2015-04-28 University Of Miami Immunomodulating tumor necrosis factor receptor 25 (TNFR25) agonists, antagonists, and immunotoxins
US9499627B2 (en) 2009-08-03 2016-11-22 University Of Miami Method for in vivo expansion of T regulatory cells

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003013581A1 (en) * 2001-08-03 2003-02-20 Genset S.A. Agonists and antagonists of genceptin for the treatment of metabolic disorders
CA2536086C (en) * 2003-08-20 2013-03-19 University Of Miami Inhibition of dr3 in the treatment of allergic lung inflammation
GB0413688D0 (en) * 2004-06-18 2004-07-21 Novartis Forschungsstiftung Analysis of methylated nucleic acid
EP2349315A4 (en) * 2008-10-08 2012-07-04 Univ Miami REGULATION OF LYMPHOCYTES AND USES THEREOF
CN103517918A (en) * 2011-03-01 2014-01-15 诺沃—诺迪斯克有限公司 Antagonistic DR3 ligands
US9127081B2 (en) 2012-05-10 2015-09-08 Washington University Tumor targeted TNF-related apoptosis inducing ligand fusion polypeptide and nucleic acids encoding the same
CA2897826C (en) 2013-01-09 2022-09-27 Taylor H. Schreiber Compositions and methods for the regulation of t regulatory cells using tl1a-ig fusion protein
JP2017511381A (en) * 2014-04-04 2017-04-20 協和発酵キリン株式会社 Anti-death receptor 3 (DR3) antagonist antibody with reduced agonist activity
GB202315963D0 (en) 2023-10-18 2023-11-29 Cancer Research Tech Ltd Binding molecules

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997033904A1 (en) * 1996-03-12 1997-09-18 Human Genome Sciences, Inc. Death domain containing receptors
WO1997037020A1 (en) * 1996-04-01 1997-10-09 Genentech, Inc. Apo-2li and apo-3 apoptosis polypeptides
WO1998005783A1 (en) * 1996-08-07 1998-02-12 Biogen, Inc. A tumor necrosis factor related ligand
WO1999019490A1 (en) * 1997-10-10 1999-04-22 Genentech, Inc. Apo-3 ligand
WO2000064465A1 (en) * 1999-04-22 2000-11-02 Human Genome Sciences, Inc. Death domain containing receptors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6462176B1 (en) * 1996-09-23 2002-10-08 Genentech, Inc. Apo-3 polypeptide

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997033904A1 (en) * 1996-03-12 1997-09-18 Human Genome Sciences, Inc. Death domain containing receptors
WO1997037020A1 (en) * 1996-04-01 1997-10-09 Genentech, Inc. Apo-2li and apo-3 apoptosis polypeptides
WO1998005783A1 (en) * 1996-08-07 1998-02-12 Biogen, Inc. A tumor necrosis factor related ligand
WO1999019490A1 (en) * 1997-10-10 1999-04-22 Genentech, Inc. Apo-3 ligand
WO2000064465A1 (en) * 1999-04-22 2000-11-02 Human Genome Sciences, Inc. Death domain containing receptors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
S. NEWMAN ET AL.: "Neuron-specific localisation of the TR3 death receptor in Alzheimer's disease.", BRAIN RESEARCH, vol. 857, no. 1-2, 28 February 2000 (2000-02-28), Amsterdam, The Netherlands, pages 131 - 140, XP000990597 *
See also references of EP1231937A2 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9017679B2 (en) 2005-08-30 2015-04-28 University Of Miami Immunomodulating tumor necrosis factor receptor 25 (TNFR25) agonists, antagonists, and immunotoxins
US9499627B2 (en) 2009-08-03 2016-11-22 University Of Miami Method for in vivo expansion of T regulatory cells

Also Published As

Publication number Publication date
US20050282223A1 (en) 2005-12-22
AU2006202940A1 (en) 2006-08-03
WO2001035995A2 (en) 2001-05-25
CA2391530A1 (en) 2001-05-25
JP2003514031A (en) 2003-04-15
EP1231937A2 (en) 2002-08-21
AU784504B2 (en) 2006-04-13
AU1776201A (en) 2001-05-30
MXPA02005069A (en) 2003-09-25

Similar Documents

Publication Publication Date Title
DE10085007T1 (en) Anti-infection compositions for the treatment of diseased tissue, such as cold sores
WO2004031129A3 (en) Compounds for use in the treatment of autoimmune diseases, immuno-allergical diseases and organ or tissue transplantation rejection
AU3083301A (en) Improved tissue engineered blood vessels and methods and apparatus for their manufacture
AU2001231196A1 (en) Delivery of therapeutic biological from implantable tissue matrices
WO2004009767A3 (en) Cell therapy for regeneration
EP2283866A3 (en) Methods of treatment using anti-ERBB antibody-maytansinoid conjugates
JO2373B1 (en) W-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinease Inhibitors
AU2495200A (en) Compositions and methods for the treatment of tumor
AU2003200722A1 (en) Compositions and methods for the treatment of tumor
AU2003200731A1 (en) Compositions and methods for the treatment of tumor
AU2003200740A1 (en) Compositions and methods for the treatment of tumor
WO2001000190A3 (en) Hyaluronic acid derivatives for the prevention and treatment of cutaneous scars
WO2001043732A3 (en) Use of retinoid receptor antagonists in the treatment of cartilage and bone pathologies
WO2000015247A8 (en) Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
AU3469400A (en) Pharmaceutical compositions for treatment of diseased tissues
WO2001072685A3 (en) Polyamine analogues as cytotoxic agents
MXPA02005069A (en) Tr3 specific binding agents and methods for their use.
HK1047707A1 (en) Use of (+)-tramadol, o-demethyltramadol or (+)-o-demethyltramadol, o-desmethyl-n-mono-desmethyl-tramadol or (+)-o-desmethyl-n-mono-desmethyl-tramadol for treating urinary incontinence
WO2001068828A3 (en) Compositions and methods for regulated protein expression in gut
AU6583700A (en) Proteins, genes and their use for diagnosis and treatment of breast cancer
WO2002092013A3 (en) Methods for treating liver disease and liver damage with growth hormone and foxm1b
WO2003102162A3 (en) Novel tolerogenic dendritic cells and therapeutic uses therefor
WO1999056666A8 (en) The treatment of sexual dysfunction in certain patient groups
AU2001234831A1 (en) Magnetoliposome composition for targeted treatment of biological tissue and associated methods
AU7944700A (en) Bio-artificial substrate for the production of animal and, in particular, human tissues and organs

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2391530

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/005069

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2001 537985

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2000980509

Country of ref document: EP

Ref document number: 17762/01

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2000980509

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10204419

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642